AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported updated Phase 3 SERENA-6 trial results showing that camizestrant combined with a CDK4/6 inhibitor continued to deliver significant progression-free survival benefits in hormone receptor-positive, HER2-negative advanced breast cancer.
• AstraZeneca stock is trending lower. Why are AZN shares declining?
Updated SERENA-6 Data Reinforces Progression-Free Survival Benefit
The updated analysis showed the camizestrant combination reduced the risk of disease progression or death by 55% compared with the aromatase inhibitor regimen.
Median progression-free survival reached 16.8 months for patients receiving camizestrant, versus 9.2 months for those who remained on aromatase inhibitor therapy, representing an improvement of 7.6 months.
